Hims & Hers Health, Inc. (NYSE:HIMS) COO Sells $171,329.58 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) COO Melissa Baird sold 11,751 shares of the company’s stock in a transaction on Friday, April 5th. The shares were sold at an average price of $14.58, for a total transaction of $171,329.58. Following the sale, the chief operating officer now owns 538,932 shares of the company’s stock, valued at approximately $7,857,628.56. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Melissa Baird also recently made the following trade(s):

• On Monday, April 8th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $14.74, for a total transaction of $173,209.74.
• On Wednesday, March 6th, Melissa Baird sold 11,751 shares of Hims & Hers Health stock. The shares were sold at an average price of $13.99, for a total transaction of $164,396.49.

Hims & Hers Health Stock Performance

NYSE HIMS traded up $0.37 on Monday, reaching $14.88. The company had a trading volume of 3,352,460 shares, compared to its average volume of 4,715,257. The firm has a market capitalization of $3.19 billion, a price-to-earnings ratio of -135.27 and a beta of 0.91. Hims & Hers Health, Inc. has a 1-year low of $5.65 and a 1-year high of $17.16. The company’s fifty day moving average is $12.64 and its 200-day moving average is $9.38.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 26th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.03. The firm had revenue of $246.60 million during the quarter, compared to analyst estimates of $245.84 million. Hims & Hers Health had a negative net margin of 2.70% and a negative return on equity of 7.21%. The company’s revenue for the quarter was up 47.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.05) EPS. On average, research analysts forecast that Hims & Hers Health, Inc. will post 0.1 earnings per share for the current year.

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. CM Wealth Advisors LLC acquired a new position in shares of Hims & Hers Health during the 2nd quarter worth about $25,000. Point72 Middle East FZE acquired a new position in shares of Hims & Hers Health during the 4th quarter worth about $29,000. Captrust Financial Advisors boosted its stake in shares of Hims & Hers Health by 1,827.4% during the 1st quarter. Captrust Financial Advisors now owns 6,765 shares of the company’s stock worth $36,000 after buying an additional 6,414 shares during the last quarter. Harbour Investments Inc. boosted its stake in shares of Hims & Hers Health by 427.9% during the 3rd quarter. Harbour Investments Inc. now owns 6,995 shares of the company’s stock worth $44,000 after buying an additional 5,670 shares during the last quarter. Finally, Belpointe Asset Management LLC acquired a new position in shares of Hims & Hers Health during the 1st quarter worth about $46,000. 63.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have commented on HIMS. Citigroup upped their target price on shares of Hims & Hers Health from $12.00 to $16.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. Guggenheim upped their target price on shares of Hims & Hers Health from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. SVB Leerink assumed coverage on shares of Hims & Hers Health in a research report on Monday, February 26th. They set a “market perform” rating and a $10.00 target price for the company. Truist Financial upped their price objective on shares of Hims & Hers Health from $10.00 to $13.00 and gave the company a “hold” rating in a research report on Tuesday, February 27th. Finally, TheStreet upgraded shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Moderate Buy” and an average target price of $13.45.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.